Eribulin
- Generic Name
- Eribulin
- Brand Names
- Halaven, Eribulin Baxter, Mevlyq
- Drug Type
- Small Molecule
- Chemical Formula
- C40H59NO11
- CAS Number
- 253128-41-5
- Unique Ingredient Identifier
- LR24G6354G
- Background
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid ...
- Indication
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
- Associated Conditions
- Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
- Associated Therapies
- -
Eribulin and Lenvatinib in Advanced Solid Tumors
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Virginia G. Kaklamani
- Target Recruit Count
- 29
- Registration Number
- NCT02640508
- Locations
- 🇺🇸
Cancer Therapy and Research Center University of Texas Health Science Center San Antonio, San Antonio, Texas, United States
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 22
- Registration Number
- NCT02623972
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2015-11-30
- Lead Sponsor
- Istituti Ospitalieri di Cremona
- Target Recruit Count
- 1
- Registration Number
- NCT02616848
- Locations
- 🇮🇹
AO Cremona, Cremona, Lombardia, Italy
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 2
- Registration Number
- NCT02596503
- Locations
- 🇺🇸
University of Texas, Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
- Conditions
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT02581839
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)
- Conditions
- Interventions
- First Posted Date
- 2015-10-12
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 529
- Registration Number
- NCT02574455
- Locations
- 🇺🇸
Southern Cancer Center, 29653 Anchor Cross Blvd, Daphne, Alabama, United States
🇺🇸Souther Cancer Center, 3719 Dauphin St., 5 Floor, Mobile, Alabama, United States
🇺🇸Southern Cancer Center, 3 Mobile Infirmary Circle, Mobile, Alabama, United States
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
- Conditions
- Interventions
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 622
- Registration Number
- NCT02555657
Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2021-06-11
- Target Recruit Count
- 201
- Registration Number
- NCT02551263
- Locations
- 🇯🇵
Kobe City Medical Center General Hospital, Kobe-city, Hyogo-prefecture, Japan
🇯🇵Kyoto University Hospital, Kyoto-city, Kyoto-prefecture, Japan
A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer
- First Posted Date
- 2015-08-04
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Japan Breast Cancer Research Group
- Target Recruit Count
- 370
- Registration Number
- NCT02514681
- Locations
- 🇯🇵
Japan Breast Cancer Research Group, Chuo-ku, Nihonbashi, Koami-cho, Tokyo, Japan
🇯🇵Kumamoto University Hospital, Kumamoto City, Kumamoto, Japan
🇯🇵Aichi Cancer Center, Chikusa-ku, Aichi, Japan
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 258
- Registration Number
- NCT02513472
- Locations
- 🇺🇸
Facility #2, San Antonio, Texas, United States
🇺🇸Facility #1, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.